Rexahn Pharmaceuticals (RNN)
Rexahn Pharmaceuticals Historical Price Data
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| May 30, 2012 | 0.41 | 0.4401 | 0.38 | 0.408 | 175296 |
| May 29, 2012 | 0.4179 | 0.418 | 0.40 | 0.40 | 33215 |
| May 25, 2012 | 0.401 | 0.41 | 0.38 | 0.3901 | 33713 |
| May 24, 2012 | 0.41 | 0.41 | 0.39 | 0.40 | 24037 |
| May 23, 2012 | 0.41 | 0.43 | 0.3826 | 0.41 | 57649 |
| May 22, 2012 | 0.43 | 0.4301 | 0.40 | 0.40 | 69469 |
| May 21, 2012 | 0.40 | 0.429 | 0.3626 | 0.41 | 174604 |
| May 18, 2012 | 0.41 | 0.43 | 0.35 | 0.40 | 464381 |
| May 17, 2012 | 0.42 | 0.44 | 0.42 | 0.4295 | 45988 |
| May 16, 2012 | 0.44 | 0.457 | 0.42 | 0.42 | 77125 |
| May 15, 2012 | 0.45 | 0.4599 | 0.4295 | 0.44 | 108474 |
| May 14, 2012 | 0.45 | 0.45 | 0.4402 | 0.45 | 42713 |
| May 11, 2012 | 0.46 | 0.46 | 0.429 | 0.45 | 41556 |
| May 10, 2012 | 0.435 | 0.46 | 0.42 | 0.46 | 156235 |
| May 9, 2012 | 0.4315 | 0.435 | 0.42 | 0.42 | 73910 |
| May 8, 2012 | 0.445 | 0.4455 | 0.43 | 0.43 | 56235 |
| May 7, 2012 | 0.4799 | 0.48 | 0.428 | 0.448 | 19564 |
| May 4, 2012 | 0.4311 | 0.45 | 0.43 | 0.43 | 116150 |
| May 3, 2012 | 0.4499 | 0.4499 | 0.43 | 0.43 | 77008 |
| May 2, 2012 | 0.4315 | 0.45 | 0.43 | 0.4468 | 54758 |
| May 1, 2012 | 0.43 | 0.4599 | 0.43 | 0.43 | 57854 |
| April 30, 2012 | 0.45 | 0.47 | 0.428 | 0.43 | 171219 |
| April 27, 2012 | 0.45 | 0.45 | 0.4299 | 0.435 | 55798 |
| April 26, 2012 | 0.48 | 0.48 | 0.42 | 0.428 | 137225 |
| April 25, 2012 | 0.45 | 0.4671 | 0.4428 | 0.4505 | 123220 |
| April 24, 2012 | 0.4678 | 0.4678 | 0.45 | 0.45 | 100886 |
| April 23, 2012 | 0.44 | 0.468 | 0.44 | 0.46 | 19570 |
| April 20, 2012 | 0.487 | 0.487 | 0.45 | 0.4579 | 43203 |
| April 19, 2012 | 0.46 | 0.4848 | 0.4501 | 0.474 | 53819 |
| April 18, 2012 | 0.46 | 0.4635 | 0.45 | 0.46 | 44100 |
| April 17, 2012 | 0.46 | 0.48 | 0.45 | 0.458 | 51572 |
| April 16, 2012 | 0.5699 | 0.5699 | 0.451 | 0.4563 | 48143 |
| April 13, 2012 | 0.4644 | 0.465 | 0.45 | 0.4578 | 67300 |
| April 12, 2012 | 0.4501 | 0.4595 | 0.45 | 0.4535 | 79281 |
| April 11, 2012 | 0.48 | 0.48 | 0.44 | 0.4601 | 53675 |
| April 10, 2012 | 0.45 | 0.46 | 0.43 | 0.44 | 146458 |
| April 9, 2012 | 0.4555 | 0.51 | 0.45 | 0.45 | 566276 |
| April 5, 2012 | 0.49 | 0.50 | 0.48 | 0.49 | 195782 |
| April 4, 2012 | 0.516 | 0.516 | 0.48 | 0.49 | 195066 |
| April 3, 2012 | 0.52 | 0.55 | 0.504 | 0.51 | 283384 |
| April 2, 2012 | 0.55 | 0.57 | 0.52 | 0.5252 | 308054 |
| March 30, 2012 | 0.5275 | 0.64 | 0.52 | 0.53 | 744837 |
| March 29, 2012 | 0.495 | 0.52 | 0.483 | 0.52 | 291179 |
| March 28, 2012 | 0.50 | 0.50 | 0.482 | 0.495 | 44059 |
| March 27, 2012 | 0.49 | 0.50 | 0.481 | 0.485 | 104560 |
| March 26, 2012 | 0.4833 | 0.4978 | 0.48 | 0.48 | 141991 |
| March 23, 2012 | 0.50 | 0.5028 | 0.48 | 0.48 | 28016 |
| March 22, 2012 | 0.49 | 0.503 | 0.48 | 0.49 | 72574 |
| March 21, 2012 | 0.482 | 0.49 | 0.48 | 0.48 | 88250 |
| March 20, 2012 | 0.503 | 0.51 | 0.48 | 0.4886 | 78366 |
RNN News
Rexahn Pharmaceuticals Announces Publication of New Preclinical Research Data for Novel Anti-Cancer Compound RX-3117
May 30, 8:00AM Business Wire
May 30, 8:00AM Business Wire
Rexahn Pharmaceuticals Submits Archexin Phase II Protocol for Ovarian Cancer to FDA
May 08, 8:02AM Benzinga
May 08, 8:02AM Benzinga
Rexahn Pharmaceuticals Issued Japanese Patent for New Anti-cancer Compounds
Apr 30, 8:00AM Business Wire
Apr 30, 8:00AM Business Wire
$RNN filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/3XOX
about 35 days ago by MarketBrief
about 35 days ago by MarketBrief
Rexahn Pharmaceuticals to Present Data on Novel Anti-Cancer Small Molecule RX-3117 at AACR 103rd Annual Meeting
Mar 27, 8:00AM Business Wire
Mar 27, 8:00AM Business Wire
Rexahn Pharmaceuticals Enrolls First Subject in Exploratory Phase I Clinical Study of RX-3117
Mar 13, 8:02AM Benzinga
Mar 13, 8:02AM Benzinga
Rexahn Pharmaceuticals Publishes New Preclinical Data for Quinoxalinyl-Piperazine Compounds
Jan 25, 8:00AM Benzinga
Jan 25, 8:00AM Benzinga
Rodman & Renshaw Changes Rating on Rexahn Pharmaceuticals to Market Perform
Jan 18, 12:44PM Benzinga
Jan 18, 12:44PM Benzinga
Rexahn Pharmaceuticals (RNN) Receives Approval in Europe to Conduct a First-in-Human Trial of RX-3117
Jan 18, 8:03AM Street Insider
Jan 18, 8:03AM Street Insider
Drug Candidates From Rexahn and Elite Pharmaceuticals Look to Pass Key Tests
Nov 09, 8:16AM Marketwire
Nov 09, 8:16AM Marketwire
Rexahn Pharmaceuticals (RNN) Offers Results from Phase II Trial of Serdaxin for Major Depressive Disorder
Nov 04, 8:26AM Street Insider
Nov 04, 8:26AM Street Insider
Rexahn Pharmaceuticals Announces Phase II Results for Serdaxin® as Treatment for Major Depressive Disorder
Nov 04, 8:00AM Business Wire
Nov 04, 8:00AM Business Wire
Rexahn Pharmaceuticals granted U.S. patent for isoquinolinamine compounds
Oct 12, 8:01AM FlyOnTheWall
Oct 12, 8:01AM FlyOnTheWall
Rexahn Pharmaceuticals Granted US Patent for Novel Anti-cancer Isoquinolinamine Compounds
Oct 12, 8:00AM Business Wire
Oct 12, 8:00AM Business Wire
Rexahn Pharmaceuticals Announces Publication of Study Validating Mechanism of Action of Serdaxin®
Oct 03, 8:00AM Business Wire
Oct 03, 8:00AM Business Wire
Rexahn Pharmaceuticals to Present at the Rodman & Renshaw 13th Annual Healthcare Conference
Sep 08, 8:00AM Business Wire
Sep 08, 8:00AM Business Wire
Rexahn Pharmaceuticals announces patent for neurotherapeutic compositions
Aug 08, 9:03AM FlyOnTheWall
Aug 08, 9:03AM FlyOnTheWall
$RNN http://chart.ly/bxxaome Do not like the Company at all; however they have done some excellent P&D. very tight range.
about 307 days ago by Wiserguy1971
about 307 days ago by Wiserguy1971
sold the $RNN I've been holding for at least a month at 1.21 for small loss. don't like the large shelf offering
about 343 days ago by LitheLyricist
about 343 days ago by LitheLyricist
RT @ABtrader $RNN sees completing Trial, announcing Prelim Results before Yr End = Should see some big action today.
about 344 days ago by epollux
about 344 days ago by epollux
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| RNN | 0.408 | +0.00 | +0.00% | 38.90M |
| RNIN | 0.76 | +0.01 | +1.33% | 17.46M |
| RNF | 23.85 | +0.45 | +1.92% | |
| RNET | 15.33 | +0.13 | +0.86% | 234.69M |
| RNE | 13.72 | -0.25 | -1.79% | |
| RMTR | 1.86 | -0.10 | -5.10% | 69.24M |
| RMT | 8.70 | -0.02 | -0.23% | |
| RMKR | 0.65 | +0.02 | +3.14% | 17.43M |
| RMD | 30.70 | -0.42 | -1.35% | 4.487B |
| RMCF | 10.45 | -0.01 | -0.10% | 64.05M |